Fabian L.
- Country
- Germany
- Department
- 2501: Medizinische Klinik II
Research Overview
- Long-term Safety of Asciminib in Patients With Philadelphia Chromosome-Positive CML or ALL Continuing From Parent Studies
- Phase II Open‑Label Multicenter Study of Autologous Dual‑CAR T‑Cell Therapy (AUTO1) in Ph‑negative CD19⁺ B‑precursor ALL Patients with MRD ≥10⁻⁴ in First Remission
- Evaluation of Tolerability and Efficacy of Asciminib Hydrochloride Versus Nilotinib in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Data & Insights
Has run more than one trial at 84 of 209 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in the treatment of advanced hematologic malignancies, with particular emphasis on developing innovative therapeutic approaches for blood-based cancers.
- Novel therapeutic agents evaluation
- Blood cancer treatment strategies
- Monotherapy and combination approaches
Their research encompasses both standalone treatments and combination therapies for various blood cancers.
Chronic Myeloid Leukemia
The investigator has extensive experience in treating chronic myeloid leukemia (CML), focusing on developing and evaluating targeted therapies, particularly in the chronic phase of the disease.
- First-line treatment optimization
- Tyrosine kinase inhibitor therapy
- Molecular response assessment
Their work includes evaluation of novel BCR-ABL1 inhibitors and treatment strategies for newly diagnosed patients.
Treatment-Resistant CML
The investigator focuses on developing solutions for treatment-resistant CML cases, particularly in patients who have undergone multiple prior therapies.
- Third-line treatment strategies
- Drug tolerability assessment
- Long-term disease management
Their research includes optimization of treatment protocols for patients with limited therapeutic options.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.